• Explore /
  • Poster
  • / Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.

Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.

Abstract Poster

Authors

Sayeh Lavasani

Sayeh Moazami Lavasani

City of Hope National Medical Center, Duarte, CA

Sayeh Moazami Lavasani , Susan Elaine Yost , Paul Henry Frankel , Christopher Ruel , Mireya Murga , Aileen Tang , Norma Martinez , Laura Kruper , Lusine Tumyan , Dan Schmolze , Francesca Menghi , Edison T. Liu , Christina Haeyoung Yeon , Yuan Yuan , James Ross Waisman , George Somlo , Joanne E. Mortimer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT01730833

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 583)

DOI

10.1200/JCO.2021.39.15_suppl.583

Abstract #

583

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Nicholas Patrick McAndrew

First Author: Jennifer Gao

First Author: Xiaowen Ding

First Author: Hong-Fei Gao